Overview

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Status:
Completed

Trial end date:
2021-02-15

Target enrollment:

Participant gender:

Summary

The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Gastric Inhibitory Polypeptide
Metformin
Tirzepatide